The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress

Molecular and Cellular Neuroscience

Volumn 47, Issue 2, 2011, Pages 145-153

  Sanghera, Karan P ^a,b   Mathalone, Nurit ^a,b   Baigi, Ramteen ^a,b   Panov, Elan ^a,b   Wang, Dan ^c   Zhao, Xu ^a,b   Hsu, Howard ^a,b   Wang, Hai ^a,b   Tropepe, Vincent ^a,c,d   Ward, Michael ^e   Boyd, Shelley R ^a,b,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Department of Cell and Systems Biology ^*  (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Apoptosis; Erythropoietin; Hypoxia; Insulin; Neural stem cell; Retinal progenitor cell; Superoxide

Indexed keywords

HYDROGEN PEROXIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; SUPEROXIDE;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL HYPOXIA; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; EX VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; OXYGEN CONCENTRATION; OXYGEN TENSION; PRIORITY JOURNAL; RETINA CELL; SIGNAL TRANSDUCTION; STEM CELL; UPREGULATION;

ANIMALS; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; ERYTHROPOIETIN; HYDROGEN PEROXIDE; INSULIN; MICE; OXIDANTS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RETINA; SIGNAL TRANSDUCTION; STEM CELLS; STRESS, PHYSIOLOGICAL; SUPEROXIDES; TOR SERINE-THREONINE KINASES;

EID: 79955972156     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2011.03.010     Document Type: Article

References (51)

1. Aguirre D., Boya P., Bellet D., Faivre S., Troalen F., Benard J., Saulnier P., Hopkins-Donaldson S., Zangemeister-Wittke U., Kroemer G., Raymond E. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004, 9:797-805.
2. Barber A.J., Nakamura M., Wolpert E.B., Reiter C.E., Seigel G.M., Antonetti D.A., Gardner T.W. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J. Biol. Chem. 2001, 276:32814-32821.
3. Becerra S.P., Amaral J. Erythropoietin-an endogenous retinal survival factor. N. Engl. J. Med. 2002, 347:1968-1970.
4. Boulton S., Kyle S., Yalcintepe L., Durkacz B.W. Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells. Carcinogenesis 1996, 17:2285-2290.
5. Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence J.C., Abraham R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996, 15:5256-5267.
6. Chen Z.Y., Warin R., Noguchi C.T. Erythropoietin and normal brain development: receptor expression determines multi-tissue response. Neurodegener. Dis. 2006, 3:68-75.
7. Chung H., Lee H., Lamoke F., Hrushesky W.J., Wood P.A., Jahng W.J. Neuroprotective role of erythropoietin by antiapoptosis in the retina. J. Neurosci. Res. 2009, 87:2365-2374.
8. Cipolleschi M.G., Dello Sbarba P., Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 1993, 82:2031-2037.
9. Clarke L., van der Kooy D. Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways. Stem Cells 2009, 27:1879-1886.
10. Corbacioglu S., Kilic M., Westhoff M.A., Reinhardt D., Fulda S., Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006, 108:3504-3513.
11. Dame C., Bartmann P., Wolber E., Fahnenstich H., Hofmann D., Fandrey J. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res. Dev. Brain Res. 2000, 125:69-74.
12. Dennis P.B., Jaeschke A., Saitoh M., Fowler B., Kozma S.C., Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294:1102-1105.
13. Eliasson P., Jonsson J.I. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J. Cell. Physiol. 2010, 222:17-22.
14. Garcia-Martinez J.M., Moran J., Clarke R.G., Gray A., Cosulich S.C., Chresta C.M., Alessi D.R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421:29-42.
15. Geske F.J., Lieberman R., Strange R., Gerschenson L.E. Early stages of p53-induced apoptosis are reversible. Cell Death Differ. 2001, 8:182-191.
16. Grimm C., Hermann D.M., Bogdanova A., Hotop S., Kilic U., Wenzel A., Kilic E., Gassmann M. Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. Semin. Cell Dev. Biol. 2005, 16:531-538.
17. Grimm C., Wenzel A., Acar N., Keller S., Seeliger M., Gassmann M. Hypoxic preconditioning and erythropoietin protect retinal neurons from degeneration. Adv. Exp. Med. Biol. 2006, 588:119-131.
18. Grimm C., Wenzel A., Groszer M., Mayser H., Seeliger M., Samardzija M., Bauer C., Gassmann M., Reme C.E. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 2002, 8:718-724.
19. Grimm C., Wenzel A., Stanescu D., Samardzija M., Hotop S., Groszer M., Naash M., Gassmann M., Reme C. Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J. Neurosci. 2004, 24:5651-5658.
20. Holzwarth C., Vaegler M., Gieseke F., Pfister S.M., Handgretinger R., Kerst G., Muller I. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol. 2010, 11:11.
21. Junk A.K., Mammis A., Savitz S.I., Singh M., Roth S., Malhotra S., Rosenbaum P.S., Cerami A., Brines M., Rosenbaum D.M. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 2002, 99:10659-10664.
22. Juul S.E., Yachnis A.T., Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 1998, 52:235-249.
23. Kilic U., Kilic E., Soliz J., Bassetti C.I., Gassmann M., Hermann D.M. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J. 2005, 19:249-251.
24. Mohyeldin A., Garzon-Muvdi T., Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
25. Morita M., Ohneda O., Yamashita T., Takahashi S., Suzuki N., Nakajima O., Kawauchi S., Ema M., Shibahara S., Udono T., Tomita K., Tamai M., Sogawa K., Yamamoto M., Fujii-Kuriyama Y. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003, 22:1134-1146.
26. Panchision D.M. The role of oxygen in regulating neural stem cells in development and disease. J. Cell. Physiol. 2009, 220:562-568.
27. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30:e36.
28. Rafalski V.A., Brunet A. Energy metabolism in adult neural stem cell fate. Prog. Neurobiol. 2010.
29. Rex T.S., Wong Y., Kodali K., Merry S. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Exp. Eye Res. 2009, 89:735-740.
30. Santilli G., Lamorte G., Carlessi L., Ferrari D., Rota Nodari L., Binda E., Delia D., Vescovi A.L., De Filippis L. Mild hypoxia enhances proliferation and multipotency of human neural stem cells. PLoS One 2010, 5:e8575.
31. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
32. Seigel G.M., Mutchler A.L., Imperato E.L. Expression of glial markers in a retinal precursor cell line. Mol. Vis. 1996, 2:2.
33. Seigel G.M., Sun W., Wang J., Hershberger D.H., Campbell L.M., Salvi R.J. Neuronal gene expression and function in the growth-stimulated R28 retinal precursor cell line. Curr. Eye Res. 2004, 28:257-269.
34. Semenza G.L. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol. Oncol. Clin. North Am. 1994, 8:863-884.
35. Semenza G.L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 1999, 15:551-578.
36. Shen J., Wu Y., Xu J.Y., Zhang J., Sinclair S.H., Yanoff M., Xu G., Li W., Xu G.T. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest. Ophthalmol. Vis. Sci. 2009, 51:35-46.
37. Silvan U., Diez-Torre A., Arluzea J., Andrade R., Silio M., Arechaga J. Hypoxia and pluripotency in embryonic and embryonal carcinoma stem cell biology. Differentiation 2009, 78:159-168.
38. Simon M.C., Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat. Rev. Mol. Cell Biol. 2008, 9:285-296.
39. Singleton P.A., Mambetsariev N., Lennon F.E., Mathew B., Siegler J.H., Moreno-Vinasco L., Salgia R., Moss J., Garcia J.G. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res 2010, 2:5.
40. Siren A.L., Fasshauer T., Bartels C., Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009, 6:108-127.
41. Siren A.L., Knerlich F., Poser W., Gleiter C.H., Bruck W., Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 2001, 101:271-276.
42. Tekkok S.B., Brown A.M., Ransom B.R. Axon function persists during anoxia in mammalian white matter. J. Cereb. Blood Flow Metab. 2003, 23:1340-1347.
43. Tropepe V., Coles B.L., Chiasson B.J., Horsford D.J., Elia A.J., McInnes R.R., van der Kooy D. Retinal stem cells in the adult mammalian eye. Science 2000, 287:2032-2036.
44. Tsai J.C., Wu L., Worgul B., Forbes M., Cao J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr. Eye Res. 2005, 30:1025-1031.
45. Wallach I., Zhang J., Hartmann A., van Landeghem F.K., Ivanova A., Klar M., Dame C. Erythropoietin-receptor gene regulation in neuronal cells. Pediatr. Res. 2009, 65:619-624.
46. Weishaupt J.H., Rohde G., Polking E., Siren A.L., Ehrenreich H., Bahr M. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2004, 45:1514-1522.
47. Wipf P., Minion D.J., Halter R.J., Berggren M.I., Ho C.B., Chiang G.G., Kirkpatrick L., Abraham R., Powis G. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Org. Biomol. Chem. 2004, 2:1911-1920.
48. Yu D.Y., Cringle S.J. Retinal degeneration and local oxygen metabolism. Exp. Eye Res. 2005, 80:745-751.
49. Yu X., Shacka J.J., Eells J.B., Suarez-Quian C., Przygodzki R.M., Beleslin-Cokic B., Lin C.S., Nikodem V.M., Hempstead B., Flanders K.C., Costantini F., Noguchi C.T. Erythropoietin receptor signalling is required for normal brain development. Development 2002, 129:505-516.
50. Yuan H., Pupo M.T., Blois J., Smith A., Weissleder R., Clardy J., Josephson L. A stabilized demethoxyviridin derivative inhibits PI3 kinase. Bioorg. Med. Chem. Lett. 2009, 19:4223-4227.
51. Zhong L., Bradley J., Schubert W., Ahmed E., Adamis A.P., Shima D.T., Robinson G.S., Ng Y.S. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest. Ophthalmol. Vis. Sci. 2007, 48:1212-1218.